One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART StudyCamilla Muccini, Antonella Castagna, Sara Diotallevi et al.|Open Forum Infectious Diseases|2024Cited by 20
Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Laura Comi, Maurizio Zazzi et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 7
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Alessio Bellucci, Maurizio Zazzi et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 6
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registryTommaso Clemente, Flavia Balena, Antonio Di Biagio et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 2
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO RegistryDaniele Armenia, Silvia Magnani, Maurizio Zazzi et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 0